Meritxell Bernat Fuertes

Meritxell Bernat Fuertes has a diverse and extensive work experience in the pharmaceutical industry. Meritxell currently serves as the Medical Director Southern Europe at Aimmune Therapeutics since November 2021. Prior to that, they worked at Novartis Gene Therapies as the Head Medical Affairs, Italy - Executive Medical Director from March 2019 to November 2021.

Before Novartis, they held positions at Sanofi Genzyme, where they worked as the Medical Director Europe - Rare Diseases from February 2016 to March 2019, and as the Medical Manager - Rare Diseases from January 2013 to February 2016. Additionally, they have experience working at Boehringer Ingelheim as a Clinical Research Manager and Global Clinical Trial Lead from 2008 to 2012, and at Pfizer as a Global Drug Safety Physician and COX-2 Project Pharmacoepidemiologist from 2005 to 2008.

Earlier in their career, Meritxell Bernat Fuertes worked at Hospital Universitari de la Vall d'Hebron as a Clinical Pharmacology Resident, Assistant Physician, and Emergency Room Doctor from 2001 to 2005. Meritxell also had a research trainee role at Istituto Mario Negri in 2005 and served as a Medical Consultant at Novartis Consumer Health in 2001.

Overall, Meritxell Bernat Fuertes has a strong background in medical affairs, clinical research, drug safety, and pharmacovigilance in the pharmaceutical industry.

Meritxell Bernat Fuertes completed a medical degree at Universitat Autònoma de Barcelona from 1993 to 1999. Meritxell then pursued a Clinical Pharmacology residency program at Hospital Universitari de la Vall D'Hebron from 2001 to 2005, focusing on the field of Pharmacology. In 2016, Meritxell earned a Master's degree in Pharmaceutical Medicine with a specialization in pre-clinical and clinical drug development from Università Cattolica del Sacro Cuore.